Shared on 04 Nov 25
Fair value Increased 5.56%Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook. What's in the News Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025.
Shared on 21 Oct 25
Fair value Increased 16%Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.
Shared on 15 Aug 25
RT-114 And Pill Technology Will Transform Obesity Treatments
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
Shared on 01 May 25
Fair value Decreased 31%RT-114 And Pill Technology Will Transform Obesity Treatments
Shared on 24 Apr 25
Fair value Decreased 41%RT-114 And Pill Technology Will Transform Obesity Treatments
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.3%.
Shared on 17 Apr 25
Fair value Increased 142%RT-114 And Pill Technology Will Transform Obesity Treatments
AnalystConsensusTarget has decreased revenue growth from 152.5% to 129.8%, increased future PE multiple from 170.2x to 323.1x and decreased shares outstanding growth rate from 0.1% to 0.1%.